Full Text View
Tabular View
Study Results
Related Studies
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
This study has been completed.
Study NCT00439647   Information provided by Novartis

First Received on February 22, 2007.   Last Updated on October 10, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Male Osteoporosis
Additional conditions recognized in this trial
Fractures, Bone
Osteoporosis
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Wounds and Injuries
Interventions listed in this trial
Zoledronic acid 5 mg iv
Placebo
Additional drug interventions recognized in this trial
Diphosphonates
Zoledronic acid
More general drug interventions related to this trial
Bone Density Conservation Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services